We are joined by Arlene Sietker-Radtke (The University of Texas MD Anderson Cancer Center) at ESMO 2019 to discuss her presentation on the results from the KEYNOTE-866 trial (NCT03924856). This phase III study investigates perioperative pembrolizumab or placebo in combination with neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer.
What are the limitations of the current treatment of muscle-invasive bladder cancer with neoadjuvant chemotherapy? (0:04)
What is the rationale for using pembrolizumab in the perioperative treatment setting? (0:37)
Could you tell us about the aims and design of the KEYNOTE-866 study? (1:23)
What are the eligibility criteria for this study? (1:58)
What are the most promising emerging biomarkers for response to pembrolizumab in bladder cancer? (2:28)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Arlene Siefker-Radtke has participated in advisory boards for Merck.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Bladder Cancer
Alison Birtle, ASCO GU 2021: Peri-operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer
touchONCOLOGY joins Dr Alison Birtle (Consultant Oncologist and Honorary Senior Lecturer, Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK) to discuss the updated primary and secondary analysis of the POUT trial in upper tract urothelial cancer (ClinicalTrials.gov Identifier: NCT01993979). The abstract “Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance […]
Thomas Powles, ASCO20: JAVELIN Bladder 100 Phase III Interim Analysis
It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma. Questions 1. What have we learned so far from clinical trials […]
Petros Grivas, ESMO 2019 – Advances in metastatic urothelial cancer
We joined Petros Grivas (University of Washington School of Medicine) at ESMO 2019 to discuss immune checkpoint inhibitors and novel agents in the treatment of metastatic urothelial cancer. Questions 1. How have immune checkpoint inhibitors changed the treatment landscape for metastatic urothelial cancer? (0:04) 2. What progress has been made in identifying biomarkers of response […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!